Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus EDROPHONIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus EDROPHONIUM CHLORIDE.
ADLARITY vs EDROPHONIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor